Form 4: Teva Executive Sells Shares Under 10b5-1 Plan

Teva Pharmaceutical Industries Ltd. executive Matthew Shields reported a transaction involving the sale of ordinary shares acquired through restricted share units under a pre-arranged 10b5-1 trading plan.

Summary

• Matthew Shields, EVP of Global Operations at Teva Pharmaceutical Industries Ltd., engaged in a transaction on June 3, 2026.
• This transaction involved the sale of 16,195 ordinary shares.
• These shares were acquired through restricted share units (RSUs) that vested on June 3, 2026.
• The sale was executed as part of a Rule 10b5-1 trading plan adopted on November 10, 2025.
• The sale price was $32.87 per share.
• Following the transaction, Shields beneficially owns 9,989 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative signal, the transaction was conducted under a pre-established 10b5-1 plan to cover tax obligations upon vesting, which is a standard and expected event.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider trading activity.
• The sale was to cover tax withholding obligations related to the vesting of RSUs, a common and expected event.

Negatives

• An executive is selling a significant number of shares, which could be perceived negatively by the market, although it's part of a planned divestment.
• The sale reduces the executive's direct beneficial ownership of company stock.

Risks

• Potential for negative market perception due to insider selling, even if pre-planned.
• The value of the shares sold was $531,100.63 (16,195 shares * $32.87), representing a notable disposition of equity.

Future Outlook

The filing details a specific transaction and does not provide forward-looking statements or guidance regarding the company's future performance. However, it notes that further tranches of RSUs are scheduled to vest on June 3, 2027 (16,195 units) and June 3, 2028 (16,197 units), implying potential future transactions related to these grants.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executives and directors, detailing changes in their beneficial ownership of company stock. The use of a Rule 10b5-1 plan is a common strategy for executives to sell shares without triggering insider trading concerns, especially when managing compensation-related equity events like RSU vesting.

Stakeholder Impact

• Shareholders: May perceive insider selling, even if planned, as a slight negative signal, though the 10b5-1 plan mitigates this concern.
• Employees: The transaction is related to executive compensation and does not directly impact other employees.
• Management: Demonstrates adherence to corporate governance policies regarding stock transactions and compensation management.

Next Steps

• Monitoring future vesting dates for remaining restricted share units (June 3, 2027, and June 3, 2028).
• Observing any further Form 4 filings from Matthew Shields or other Teva executives.

Key Dates

Keywords

Teva Pharmaceutical Industries, Form 4, Insider Trading, 10b5-1 Plan, Matthew Shields, Restricted Share Units, Share Sale, Executive Compensation, SEC Filing